Neurofibromatosis: Difference between revisions

From WikiMD's Wellness Encyclopedia

m 1 revision imported
 
No edit summary
 
Line 1: Line 1:
{{Use dmy dates|date=July 2018}}
{{Use dmy dates|date=July 2018}}
{{Infobox medical condition (new)
{{Infobox medical condition (new)
| name           = Neurofibromatosis
| name = Neurofibromatosis
| image           = Neurofibromatosis.jpg
| image = Neurofibromatosis.jpg
| caption         = Back of an elderly woman with neurofibromatosis type 1
| caption = Back of an elderly woman with neurofibromatosis type 1
| field           = [[Neurosurgery]]
| field = [[Neurosurgery]], [[Genetics]]
| pronounce      =
| symptoms = Skin lumps, [[scoliosis]], [[hearing loss]], [[vision loss]]<ref name=NIH2016/>
| symptoms       = Small lumps within the skin, [[scoliosis]], [[hearing loss]], [[vision loss]]<ref name=NIH2016/>
| complications = [[Tumor]] growth, neurological issues, learning disabilities
| complications   =
| onset = Birth to early adulthood<ref name=NIH2016/>
| onset           = Birth to early adulthood<ref name=NIH2016/>
| duration = Lifelong<ref name=NIH2016/>
| duration       = Life long<ref name=NIH2016/>
| types = [[Neurofibromatosis type 1]] (NF1), [[Neurofibromatosis type 2]] (NF2), [[Schwannomatosis]]<ref name=NIH2016/>
| types           = [[Neurofibromatosis type 1]] (NF1), [[neurofibromatosis type 2]] (NF2), [[schwannomatosis]]<ref name=NIH2016/>
| causes = [[Genetic disorder|Genetic mutation]] (inherited or spontaneous)<ref name=NIH2016/>
| causes         = [[Genetics|Genetic]]<ref name=NIH2016/>
| diagnosis = Clinical symptoms, [[genetic testing]], [[imaging studies]]<ref name=Gen2016/>
| risks          =
| treatment = Surgery, [[radiation therapy]], [[chemotherapy]], [[cochlear implant]]s<ref name=Gen2016/>
| diagnosis       = Symptoms, [[genetic testing]]<ref name=Gen2016/>
| prognosis = '''NF1''': normal life expectancy<ref name=NIH2016/> <br>'''NF2''': shortened life expectancy<ref name=NIH2016/>
| differential    =
| frequency = 1 in 3,000 people (United States)<ref name=NIH2016/>
| prevention      =
| treatment       = Surgery, [[radiation therapy]]<ref name=Gen2016/>
| medication      =
| prognosis       = '''NF1''': normal life expectancy<ref name=NIH2016/><br>'''NF2''': shortened life expectancy<ref name=NIH2016/>
| frequency       = 1 in 3,000 people (United States)<ref name=NIH2016/>
| deaths          =
}}
}}
<!-- Definition and symptoms -->
'''Neurofibromatosis''' ('''NF''') is a group of three conditions in which [[tumors]] grow in the [[nervous system]].<ref name="NIH2016">{{cite web|url=https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Neurofibromatosis-Fact-Sheet|title=Neurofibromatosis Fact Sheet|date=3 February 2016|website=NINDS|url-status=live|archiveurl=https://web.archive.org/web/20180123034742/https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Neurofibromatosis-Fact-Sheet |archivedate=23 January 2018|accessdate=16 April 2018}}{{PD-notice}}</ref> The three types are [[neurofibromatosis type I]] (NF1), [[neurofibromatosis type II]] (NF2), and [[schwannomatosis]].<ref name=NIH2016/> In NF1 symptoms include [[Cafe au lait spots|light brown spots on the skin]], [[freckles]] in the armpit and groin, small bumps within nerves, and [[scoliosis]].<ref name=Gen2016/> In NF2, there may be [[hearing loss]], [[cataract]]s at a young age, balance problems, flesh colored skin flaps, and [[muscle atrophy|muscle wasting]].<ref name=Gen2016>{{cite web|url=https://www.genome.gov/14514225/|title=Learning about Neurofibromatosis|date=16 August 2016|website=National Human Genome Research Institute (NHGRI)|url-status=live|archiveurl=https://web.archive.org/web/20161010042216/https://www.genome.gov/14514225/|archivedate=10 October 2016|accessdate=7 November 2016}}{{PD-notice}}</ref> In schwannomatosis there may be pain either in one location or in wide areas of the body.<ref name=Gene2019/> The tumors in NF are generally [[Benign|non-cancerous]].<ref name=NIH2016 />


<!-- Cause and diagnosis -->
'''Neurofibromatosis''' ('''NF''') is a group of genetic disorders that cause the growth of tumors in the nervous system.<ref name="NIH2016">{{cite web|url=https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Neurofibromatosis-Fact-Sheet|title=Neurofibromatosis Fact Sheet|date=3 February 2016|website=NINDS|url-status=live|archiveurl=https://web.archive.org/web/20180123034742/https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Neurofibromatosis-Fact-Sheet |archivedate=23 January 2018|accessdate=16 April 2018}}</ref> It includes three distinct conditions:
The cause is a [[genetic mutation]] in certain [[genes]].<ref name=NIH2016/> These can be [[heredity|inherited from a person's parents]], or in about half of cases spontaneously occur during early development.<ref name=NIH2016/> Different mutations result in the three types of NF.<ref name=Wood2015>{{cite journal |last1=Woodrow |first1=Christopher |last2=Clarke |first2=Anna |last3=Amirfeyz |first3=Rouin |title=Neurofibromatosis |journal=Orthopaedics and Trauma |date=1 June 2015 |volume=29 |issue=3 |pages=206–210 |doi=10.1016/j.mporth.2015.02.004 |url=https://www.orthopaedicsandtraumajournal.co.uk/article/S1877-1327(15)00017-2/fulltext |accessdate=22 November 2019 |language=English |issn=1877-1327}}</ref> The tumors involve the supporting cells of the nervous system rather than the [[neurons]].<ref name=NIH2016/> In NF1 the tumors are [[neurofibromas]] (tumors of the peripheral nerves), while in NF2 and schwannomatosis [[schwannomas|tumors of Schwann cells]] are more common.<ref name=NIH2016/> Diagnosis is typically based on symptoms, examination, [[medical imaging]], and [[tissue biopsy|biopsy]].<ref name=Stat2019>{{cite journal |last1=Le |first1=C |last2=Bedocs |first2=PM |title=Neurofibromatosis |date=January 2019 |pmid=29083784}}</ref><ref name=Gene2019>{{cite journal |last1=Dhamija |first1=Radhika |last2=Plotkin |first2=Scott |last3=Asthagiri |first3=Ashok |last4=Messiaen |first4=Ludwine |last5=Babovic-Vuksanovic |first5=Dusica |title=Schwannomatosis |url=https://www.ncbi.nlm.nih.gov/books/NBK487394/ |website=GeneReviews® |publisher=University of Washington, Seattle |accessdate=21 November 2019 |date=1993|pmid=29517885 }}</ref> [[Genetic testing]] may rarely be done to support the diagnosis.<ref name=Gen2016 />
* [[Neurofibromatosis type 1]] (NF1) – More common, involves skin changes and nerve tumors.
* [[Neurofibromatosis type 2]] (NF2) – Characterized by tumors affecting the auditory nerves, leading to hearing loss.
* [[Schwannomatosis]] – Causes painful nerve tumors but does not typically affect hearing.


<!-- Prevention and treatment -->
The tumors in neurofibromatosis are generally benign (non-cancerous), but they can sometimes become malignant.<ref name=NIH2016/>
There is no known prevention or cure.<ref name=NIH2016 /><ref name=Gen2016 /> Surgery may be done to remove tumors that are causing problems or have become cancerous.<ref name=NIH2016 /> [[Radiation therapy|Radiation]] and [[chemotherapy]] may also be used if cancer occurs.<ref name=NIH2016 /> A [[cochlear implant]] or [[auditory brainstem implant]] may help some who have hearing loss due to the condition.<ref name=NIH2016 />


<!-- Epidemiology and history -->
== Signs and Symptoms ==
In the United States, about 1 in 3,500 people have NF1 and 1 in 25,000 have NF2.<ref name=NIH2016 /> Males and females are affected equally often.<ref name=Gen2016 /> In NF1, symptoms are often present at birth or develop before 10 years of age.<ref name=NIH2016 /> While the condition typically worsens with time, most people with NF1 have a normal life expectancy.<ref name=NIH2016 /> In NF2, symptoms may not become apparent until early adulthood.<ref name=NIH2016 /> NF2 increases the risk of early death.<ref name=NIH2016/> Descriptions of the condition occur as far back as the 1st century.<ref name = evans>{{cite book|last1=Evans|first1=Rosalie E. Ferner, Susan M. Huson, D. Gareth R.|title=Neurofibromatoses in clinical practice|date=2011|publisher=Springer|location=London|isbn=978-0-85729-628-3|page=1|url= https://books.google.com/books?id=Ng6MpB8sCUkC&lpg=PR4&pg=PA1|accessdate=9 October 2015|url-status=live|archiveurl=https://web.archive.org/web/20170910182704/https://books.google.com/books?id=Ng6MpB8sCUkC&lpg=PR4&pg=PA1|archivedate=10 September 2017}}</ref> It was formally described by [[Friedrich Daniel von Recklinghausen]] in 1882, after whom it was previously named.<ref name=Wood2015 />
{{See also|Neurofibromatosis type 1|Neurofibromatosis type 2|Schwannomatosis}}
The symptoms vary depending on the type of neurofibromatosis and may include:


== Signs and symptoms ==
=== Neurofibromatosis Type 1 (NF1) ===
[[File:Lisch nodules.JPG|thumb|upright=1.3|[[Lisch nodule]]s as seen in NF1]]
* Skin changes – [[Café au lait spots]], freckling in the underarms or groin.
[[File:Early neurofibromatosis.jpg|thumb|upright=1.3|Person with multiple small neurofibromas in the skin and a "café au lait spot" (bottom of photo, to the right of centre). A biopsy has been taken of one of the lesions.]]
* Nerve tumors – [[Neurofibroma]]s, which can appear under the skin or deeper in the body.
Neurofibromatosis type 1 in early life may cause learning and [[behavior]] problems – about 60% of children who have NF1 have mild difficulty in school.<ref>{{cite web|url=http://www.nhs.uk/conditions/Neurofibromatosis/pages/symptoms.aspx|title=Neurofibromatosis|website=NHS Choices|publisher=NHS|url-status=live|archiveurl=https://web.archive.org/web/20150925015544/http://www.nhs.uk/Conditions/Neurofibromatosis/Pages/Symptoms.aspx|archivedate=25 September 2015|accessdate=9 October 2015}}</ref> Signs the individual might have are as follows:<ref>{{cite web|url=http://www.ninds.nih.gov/disorders/neurofibromatosis/detail_neurofibromatosis.htm|title=Neurofibromatosis|website=NINDS|publisher=NIH|url-status=dead|archiveurl=https://web.archive.org/web/20151004194320/http://www.ninds.nih.gov/disorders/neurofibromatosis/detail_neurofibromatosis.htm|archivedate=4 October 2015|accessdate=9 October 2015}}</ref><ref name="NINDS2">{{cite web|url=http://www.ninds.nih.gov/disorders/neurofibromatosis/neurofibromatosis.htm|title=NINDS Neurofibromatosis Information Page|date=23 February 2015|url-status=dead|archiveurl=https://web.archive.org/web/20150404180516/http://www.ninds.nih.gov/disorders/neurofibromatosis/neurofibromatosis.htm|archivedate=4 April 2015|accessdate=2015-04-21}}</ref>
* Bone abnormalities – [[Scoliosis]] (curved spine) or abnormal bone development.
* Learning disabilities – Mild intellectual disability or attention deficit issues.
* Eye involvement – [[Lisch nodule]]s (tiny brown spots on the iris), [[optic glioma]]s (tumors affecting vision).


* Six or more light brown dermatological spots ("[[café au lait spot]]s")
=== Neurofibromatosis Type 2 (NF2) ===
* At least two [[neurofibroma]]s
* Hearing loss – Due to bilateral vestibular schwannomas (tumors on the auditory nerves).
* At least two growths on the eye's iris
* Balance issues – Difficulty with coordination and dizziness.
* Abnormal growth of the spine ([[scoliosis]])
* Vision problems – Early cataracts and other eye issues.
* Facial weakness or numbness – Due to tumors affecting cranial nerves.


People with neurofibromatosis type 2 can exhibit the same type of skin symptoms as type 1, but not necessarily in every case.<ref name=":5">{{Cite journal|last=Guha|first=Martin|date=2011-03-29|title=The Gale Encyclopedia of Genetic Disorders (3rd ed.)2011133Edited by Laurie J. Fundukian. The Gale Encyclopedia of Genetic Disorders (3rd ed.). Detroit, MI: Gale 2010. , {{text|ISBN}} 978 1 4144 7602 5 (print); 978 1 4144 7605 6 (e‐book) $445 (print) 3 vols|journal=Reference Reviews|volume=25|issue=3|pages=40–42|doi=10.1108/09504121111119022|issn=0950-4125}}</ref> The symptom most characteristic of NF2 is hearing loss. The hearing loss occurs due to the pressure of tumors on the acoustic nerve. The same pressure can cause headaches, dizziness, and nausea.<ref name=":5" />
=== Schwannomatosis ===
* Chronic pain – Often the first symptom.
* Multiple schwannomas – Benign tumors along nerves, but without affecting hearing.
* Nerve compression symptoms – Tingling, weakness, or numbness in affected areas.


The main symptom of schwannomatosis is localized pain. This pain is due to tissues and nerves experiencing more pressure because of nearby tumors.<ref name=":42"/>
== Causes and Genetics ==
Neurofibromatosis is genetic, caused by mutations in different genes:
* NF1 – Mutation in the '''NF1''' gene on chromosome 17, affecting neurofibromin, a tumor suppressor.
* NF2 – Mutation in the '''NF2''' gene on chromosome 22, affecting merlin, another tumor suppressor.
* Schwannomatosis – Mutations in the SMARCB1 or LZTR1 genes, also on chromosome 22.


==Cause==
NF is an autosomal dominant disorder, meaning only one parent needs to have the mutation for a child to inherit it. However, about 50% of cases arise from a spontaneous mutation, with no family history.<ref name="Gen2016">{{cite web|url=https://www.genome.gov/14514225/|title=Learning about Neurofibromatosis|date=16 August 2016|website=National Human Genome Research Institute (NHGRI)|url-status=live|archiveurl=https://web.archive.org/web/20161010042216/https://www.genome.gov/14514225/|archivedate=10 October 2016|accessdate=7 November 2016}}</ref>
[[File:Autosomal dominant - en.svg|thumb|Diagram of autosomal dominant inheritance pattern.]]
The three types of Neurofibromatosis are caused by different mutations on chromosomes. NF1 is caused by a mutation on the NF1 gene on the arm of chromosome 17.<ref name=":02">{{Cite journal|last=Woodrow|first=Christopher|last2=Clarke|first2=Anna|last3=Amirfeyz|first3=Rouin|date=2015|title=Neurofibromatosis|journal=Orthopaedics and Trauma|volume=29|issue=3|pages=206–210|doi=10.1016/j.mporth.2015.02.004}}</ref> NF2 is caused by a mutation on the NF2 tumor suppressor gene on chromosome 22.<ref name=":02" /> Schwannomatosis is caused by various mutations on chromosome 22.<ref name=":02" />


Neurofibromatosis is an [[autosomal dominant]] disorder, which means only one copy of the affected [[gene]] is needed for the disorder to develop.<ref>{{Cite journal|last=Woodrow|first=Christopher|last2=Clarke|first2=Anna|last3=Amirfeyz|first3=Rouin|date=2015-06-01|title=Neurofibromatosis|url=https://www.orthopaedicsandtraumajournal.co.uk/article/S1877-1327(15)00017-2/abstract|journal=Orthopaedics and Trauma|language=English|volume=29|issue=3|pages=206–210|doi=10.1016/j.mporth.2015.02.004|issn=1877-1327}}</ref> If one parent has neurofibromatosis, his or her children have a 50% chance of developing the condition as well. The severity of the parent's condition does not affect the child; the affected child may have mild NF1 even though it was inherited from a parent with a severe form of the disorder.<ref>{{Cite web|url=http://www.nhs.uk/conditions/neurofibromatosis/pages/causes.aspx|title=Neurofibromatosis type 1 - Causes - NHS Choices|last=Choices|first=NHS|website=www.nhs.uk|url-status=live|archiveurl=https://web.archive.org/web/20150924065741/http://www.nhs.uk/Conditions/Neurofibromatosis/Pages/Causes.aspx|archivedate=24 September 2015|accessdate=2015-10-09}}</ref> The types of neurofibromatosis are:
== Diagnosis ==
The diagnosis is based on:
* Clinical symptoms – Skin findings, nerve tumors, hearing issues.
* Medical imaging – MRI or CT scans to detect tumors.
* Genetic testing – Confirms the presence of NF-related mutations.
* Eye exams – To check for Lisch nodules or optic gliomas.


* [[Neurofibromatosis type I]], in which the nerve tissue grows tumors (neurofibromas) that may be benign, but may cause serious damage by compressing nerves and other tissues.<ref>{{Cite web|url=http://ghr.nlm.nih.gov/condition/neurofibromatosis-type-1|title=Neurofibromatosis type 1|date=5 October 2015|website=Genetics Home Reference|url-status=live|archiveurl=https://web.archive.org/web/20150910222428/http://ghr.nlm.nih.gov/condition/neurofibromatosis-type-1|archivedate=10 September 2015|accessdate=2015-10-09}}</ref>
== Treatment and Management ==
* [[Neurofibromatosis type II]], in which bilateral acoustic neuromas (tumors of the vestibulocochlear nerve or cranial nerve 8 (CN VIII) also known as schwannoma) develop, often leading to hearing loss.<ref>{{Cite web|url=http://ghr.nlm.nih.gov/condition/neurofibromatosis-type-2|title=Neurofibromatosis type 2|date=5 October 2015|website=Genetics Home Reference|url-status=live|archiveurl=https://web.archive.org/web/20150910222433/http://ghr.nlm.nih.gov/condition/neurofibromatosis-type-2|archivedate=10 September 2015|accessdate=2015-10-09}}</ref>
There is no cure for neurofibromatosis, but treatment focuses on managing symptoms and complications.
* [[Schwannomatosis]], in which painful schwannomas develop on spinal and peripheral nerves.<ref>{{Cite book|url=https://books.google.com/books?id=FQFGnXv41h0C|title=Practical Surgical Neuropathology: A Diagnostic Approach|last=Perry|first=Arie|last2=Brat|first2=Daniel J.|date=1 January 2010|publisher=Elsevier Health Sciences|isbn=978-0443069826|page=435|archiveurl=https://web.archive.org/web/20160502120635/https://books.google.com/books?id=FQFGnXv41h0C|archivedate=2 May 2016|url-status=live}}</ref>


==Pathophysiology==
=== Surgical and Medical Interventions ===
Neurofibromatosis type I is caused by a mutation on chromosome 17 encoding a cytoplasmic protein known as [[Neurofibromin 1|neurofibromin]].<ref>{{Cite web|url=http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=636|title=Orphanet: Neurofibromatosis type 1|website=www.orpha.net|url-status=live|archiveurl=https://web.archive.org/web/20151006061921/http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=636|archivedate=6 October 2015|accessdate=2015-10-13}}</ref> This protein is a [[tumor suppressor]] and therefore serves as a signal regulator of [[cell proliferation]] and differentiation. A dysfunction or lack of neurofibromin can affect regulation, and cause uncontrolled cell proliferation, leading to the tumors (neurofibromas) that characterize NF1. The neurofibromas caused by NF consist of Schwann cells, fibroblasts, perineuronal cells, mast cells and axons embedded in an extracellular matrix.<ref name=":2">{{Cite journal|last=Ferner|first=Rosalie E.|date=2007|title=Neurofibromatosis 1|journal=European Journal of Human Genetics|volume=15|issue=2|pages=131–138|doi=10.1038/sj.ejhg.5201676|pmid=16957683|issn=1476-5438|doi-access=free}}</ref><ref>{{cite journal|last1=Boyd|first1=Kevin P.|last2=Korf|first2=Bruce R.|last3=Theos|first3=Amy|date=July 2009|title=Neurofibromatosis type 1|journal=Journal of the American Academy of Dermatology|volume=61|issue=1|pages=1–14|doi=10.1016/j.jaad.2008.12.051|pmc=2716546|pmid=19539839}}</ref> Another function of neurofibromin is to bind to microtubules that play a role in the release of [[adenylyl cyclase]] and its activity.<ref name=":2" /> Adenylyl cyclase plays an essential role in cognition.<ref name=":2" /> Neurofibromin's role in the activity of adenylyl cyclase explains why patients with NF experience cognitive impairment.<ref name=":2" />
* Tumor removal – If tumors cause significant symptoms, surgery may be required.
* Radiation therapy – Used for tumors that cannot be surgically removed.
* Chemotherapy – In cases where tumors become cancerous.
* Hearing aids or cochlear implants – Help manage hearing loss in NF2.


Neurofibromatosis type II is caused by a mutation on chromosome 22.<ref name=":3">{{Cite journal|last=Lin|first=Andrew|date=2013|title=Advances in the treatment of neurofibromatosis-associated tumours|url=https://link.gale.com/apps/doc/A350792006/AONE?u=melb26933&sid=AONE&xid=f8c7dd6f|journal=Nature Reviews Clinical Oncology|volume=10|issue=11|pages=616–24|via=Gale|doi=10.1038/nrclinonc.2013.144|pmid=23939548}}</ref> The mutation falls on the NF2 tumor suppressor gene.<ref name=":3" /> The gene normally encodes a cytoplasmic protein known as merlin. The normal function of merlin is to regulate the activity of multiple growth factors, the mutated copy of the gene leads to merlin's loss of function.<ref name=":3" /> The loss of function leads to increased activity of growth factors normally regulated by merlin, leading to the formation of the tumors associated with NF2.<ref name=":3" />
=== Supportive Care ===
* Physical therapy – Helps with movement and balance issues.
* Pain management – Medications for schwannomatosis-related chronic pain.
* Educational support – For NF1-related learning disabilities.


Schwannomatosis is caused by a mutation on the SMARCB1 gene.<ref name=":42">{{Cite journal|last=Plotkin|first=Scott R.|last2=Blakeley|first2=Jaishri O.|last3=Evans|first3=D. Gareth|last4=Hanemann|first4=C. Oliver|last5=Hulsebos|first5=Theo J.M.|last6=Hunter-Schaedle|first6=Kim|last7=Kalpana|first7=Ganjam V.|last8=Korf|first8=Bruce|last9=Messiaen|first9=Ludwine|last10=Papi|first10=Laura|last11=Ratner|first11=Nancy|date=2013|title=Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria|journal=American Journal of Medical Genetics Part A|volume=161|issue=3|pages=405–416|doi=10.1002/ajmg.a.35760|pmc=4020435|pmid=23401320}}</ref> This gene is located near the NF2 tumor suppressor gene leading to the thought that schwannomatosis and NF2 were the same condition. The two conditions show different mutations on two different genes. The normal function of the SMARCB1 gene is to encode a protein called SMARCB1 that is part of a larger protein complex whose function is not completely understood.<ref name=":42" /> The complex including SMARCB1 plays a role in tumor suppression.<ref name=":42" /> The mutation of the SMARCB1 gene causes a loss of function in the complex leading to the formation of tumors indicative of schwannomatosis.<ref name=":42" />
== Prognosis ==
The outlook depends on the type:
* NF1 – Generally mild, with a normal life expectancy.
* NF2 – More severe; hearing loss and neurological complications may shorten life expectancy.
* Schwannomatosis – Pain is the main concern, but it does not typically affect lifespan.


==Diagnosis==
== Epidemiology ==
* NF1 affects 1 in 3,000 people.
* NF2 affects 1 in 25,000 people.
* Schwannomatosis affects 1 in 40,000 people.


The neurofibromatoses are considered as [[RASopathy|RASopathies]] and as members of the ''[[neurocutaneous syndrome]]s'' (''phakomatoses'').<ref name=ka>{{cite book |title=Master the Board USMLE Step 2 CK |author1=Conrad Fischer |author2=Farshad Bagheri |author3=Rajpal Manchandani |author4=Richard Pinsker |author5=Sudheer Chauhan |author6=Parenkumar Patel |author7=Mohammad Maruf |author8=Dhaval Satani |author9=Kaushik Doshi |author10=Ayaz Alwani |author11=Naveen Pathak |author12=Craigh Thurm |author13=Mohammad Babury |author14=Mahendra C. Patel |author15=Arthur Shalanov |author16=Samir Sarkar |author17=Sabiha Raouf |author18=Jebun Nahar |author19=Prakashkumar Patel |year=2010 |publisher=KAPLAN Medical |isbn=978-1-60714-653-7 |page=287}}</ref>
Males and females are affected equally.<ref name=NIH2016/>
The diagnosis of neurofibromatosis is done via the following means:<ref>{{Cite web|title = Neurofibromatosis. What is neurofibromatosis? Type 1 (NF1) {{!}} Patient|url = http://patient.info/doctor/neurofibromatosis-pro|website = Patient|accessdate = 2015-10-09|url-status = live|archiveurl = https://web.archive.org/web/20151004171048/http://patient.info/doctor/neurofibromatosis-pro|archivedate = 4 October 2015}}</ref>


{{columns-list|colwidth=30em|
== History ==
* [[Radiograph]]
* 1st Century – Early descriptions of neurofibromatosis.
* [[MRI]] or [[CT scan]]
* 1882 – Friedrich Daniel von Recklinghausen formally describes NF1.
* [[EEG]]
* 1990s-Present – Advancements in genetic testing and targeted therapies.
* [[Slit-lamp]] examination
* [[Genetic testing]]
* [[Histology]]
}}


===Differential diagnosis===
== Related Conditions ==
Conditions similar to NF include:  {{citation needed|date=April 2018}}
* [[LEOPARD syndrome]]
 
* [[Legius syndrome]]
{{columns-list|colwidth=30em|
* [[Proteus syndrome]]
* [[LEOPARD syndrome]]<ref>{{Cite book|title = Neurofibromatosis 1|url = https://www.ncbi.nlm.nih.gov/books/NBK1109/|publisher = University of Washington, Seattle|date = 2014|location = Seattle (WA)|pmid = 20301288|first = J. M.|last = Friedman|editor-first = Roberta A.|editor-last = Pagon|editor-first2 = Margaret P.|editor-last2 = Adam|editor-first3 = Holly H.|editor-last3 = Ardinger|editor-first4 = Stephanie E.|editor-last4 = Wallace|editor-first5 = Anne|editor-last5 = Amemiya|editor-first6 = Lora JH|editor-last6 = Bean|editor-first7 = Thomas D.|editor-last7 = Bird|editor-first8 = Cynthia R.|editor-last8 = Dolan|editor-first9 = Chin-To|editor-last9 = Fong|url-status = live|archiveurl = https://web.archive.org/web/20170118123311/https://www.ncbi.nlm.nih.gov/books/NBK1109/|archivedate = 18 January 2017}}</ref>
* [[Legius syndrome]]<ref>{{Cite book|title = Legius Syndrome|url = https://www.ncbi.nlm.nih.gov/books/NBK47312/|publisher = University of Washington, Seattle|date = 2015|location = Seattle (WA)|pmid = 20945555|first = David|last = Stevenson|first2 = David|last2 = Viskochil|first3 = Rong|last3 = Mao|editor-first = Roberta A.|editor-last = Pagon|editor-first2 = Margaret P.|editor-last2 = Adam|editor-first3 = Holly H.|editor-last3 = Ardinger|editor-first4 = Stephanie E.|editor-last4 = Wallace|editor-first5 = Anne|editor-last5 = Amemiya|editor-first6 = Lora JH|editor-last6 = Bean|editor-first7 = Thomas D.|editor-last7 = Bird|editor-first8 = Cynthia R.|editor-last8 = Dolan|editor-first9 = Chin-To|editor-last9 = Fong|url-status = live|archiveurl = https://web.archive.org/web/20170910182704/https://www.ncbi.nlm.nih.gov/books/NBK47312/|archivedate = 10 September 2017}}</ref>
* [[Proteus syndrome]]<ref name=elsobky2015>{{cite journal|url=|title=Orthopaedic manifestations of Proteus syndrome in a child with literature update|journal=Bone Reports|volume=3|pages=104–108|doi=10.1016/j.bonr.2015.09.004|pmid=28377973|pmc=5365241|year=2015|last1=El-Sobky|first1=Tamer Ahmed|last2=Elsayed|first2=Solaf M.|last3=El Mikkawy|first3=Dalia M.E.}}</ref>
* [[Macrodystrophia lipomatosa]]
* [[Klippel–Trénaunay syndrome]]
* [[Klippel–Trénaunay syndrome]]
* [[Parkes Weber syndrome]]
}}
==Treatment==
Surgical removal of tumors is an option; however, the risks involved should be assessed first.<ref>{{Cite web|title = Neurofibromatosis type 2 - Treatment - NHS Choices|url = http://www.nhs.uk/Conditions/neurofibromatosis-type-2/Pages/Treatment.aspx|website = www.nhs.uk|accessdate = 2015-10-11|first = NHS|last = Choices|url-status = live|archiveurl = https://web.archive.org/web/20151222143129/http://www.nhs.uk/Conditions/neurofibromatosis-type-2/Pages/Treatment.aspx|archivedate = 22 December 2015}}</ref> With regard to OPG (optic pathway gliomas), the preferred treatment is chemotherapy. However, radiotherapy is not recommended in children who present with this disorder.<ref>{{cite web|title=Complex Neufibrmatosis type 1|url=http://www.england.nhs.uk/wp-content/uploads/2013/06/b13-comp-neurofib-1.pdf|website=NHS.uk|publisher=NHS|accessdate=13 October 2015|url-status=live|archiveurl=https://web.archive.org/web/20151223050931/https://www.england.nhs.uk/wp-content/uploads/2013/06/b13-comp-neurofib-1.pdf|archivedate=23 December 2015}}</ref> It is recommended that children diagnosed with NF1 at an early age have an examination each year, which allows any potential growths or changes related to the disorder to be monitored.<ref>{{Cite web|title = Neurofibromatosis type 1 - Treatment - NHS Choices|url = http://www.nhs.uk/Conditions/Neurofibromatosis/Pages/Treatment.aspx|website = www.nhs.uk|accessdate = 2015-10-11|first = NHS|last = Choices|url-status = live|archiveurl = https://web.archive.org/web/20150926003955/http://www.nhs.uk/Conditions/Neurofibromatosis/Pages/Treatment.aspx|archivedate = 26 September 2015}}</ref>
==Prognosis==
In most cases, symptoms of NF1 are mild, and individuals live normal and productive lives. In some cases, however, NF1 can be severely debilitating and may cause cosmetic and [[psychological]] issues. The course of NF2 varies greatly among individuals.  In some cases of NF2, the damage to nearby vital structures, such as other [[cranial nerves]] and the [[brain stem]], can be life-threatening.  Most individuals with schwannomatosis have significant pain.  In some extreme cases the pain will be severe and disabling.<ref name="NINDS2"/>
==Epidemiology==
In the United States, about 1 in 3,500 people have NF1, 1 in 25,000 have NF2, and 1 in 40,000 have schwannomatosis.<ref name="NIH2016" /> Males and females are affected equally often in all three conditions.<ref name="Gen2016" /> In NF1, symptoms are often present at birth or develop before 10 years of age.<ref name="NIH2016" /> While the condition typically worsens with time, most people with NF1 have a normal life expectancy.<ref name="NIH2016" /> In NF2, symptoms may not become apparent until early adulthood.<ref name="NIH2016" /> NF2 increases the risk of early death.<ref name="NIH2016" /> Schwannomatosis symptoms develop in early childhood and can worsen with time. Typically life expectancy is unaffected in those with schwannomatosis.<ref name="Gene2019" />


==History==
== See Also ==
Descriptions of the condition occur as far back as the 1st century.<ref name = evans/> The conditions were formally described by [[Friedrich Daniel von Recklinghausen]] in 1882, after whom it was previously named.<ref name="Wood2015" />
* [[Neurofibromatosis type 1]]
* [[Neurofibromatosis type 2]]
* [[Schwannomatosis]]
* [[Genetic disorder]]


==References==
== External Links ==
{{Reflist}}
* [https://www.ninds.nih.gov/Disorders/All-Disorders/Neurofibromatosis-Information-Page National Institute of Neurological Disorders and Stroke – Neurofibromatosis Information]
* [https://www.nfnetwork.org/ Neurofibromatosis Network]
* [https://www.genome.gov/14514225/Learning-about-Neurofibromatosis Genome.gov – NF Information]


==Further reading==
{{Medical condition classification and resources}}
* {{Cite book|title = Neurofibromatosis Type 1: Molecular and Cellular Biology|url = https://books.google.com/books?id=pWlHAAAAQBAJ|publisher = Springer Science & Business Media|date = 29 January 2013|isbn = 9783642328640|first = Meena|last = Upadhyaya|first2 = David|last2 = Cooper}}
 
==External links==
{{Wikinews|Interview with Reggie Bibbs on his life with neurofibromatosis}}
* [https://www.ninds.nih.gov/Disorders/All-Disorders/Neurofibromatosis-Information-Page National Institute of Neurological Disorders and Stroke - information on Neurofibromatosis]
{{Scholia|topic}}
{{Medical condition classification and resources
| DiseasesDB      =
| ICD10          = {{ICD10|Q|85|0|q|80}}
| ICD9            = {{ICD9|237.7}}
| ICDO            = {{ICDO|9540|0}}
| OMIM            = 162200
| OMIM_mult      = {{OMIM2|101000}},{{OMIM2|162091}}
| MedlinePlus    =
| eMedicineSubj  = derm
| eMedicineTopic  = 287
| MeshID          = D017253
}}
{{Nervous tissue tumors}}
{{Nervous tissue tumors}}
{{Phakomatoses}}
{{Phakomatoses}}
 
{{stub}}
{{Authority control}}
 
[[Category:PNS neoplasia]]
[[Category:PNS neoplasia]]
[[Category:Genodermatoses]]
[[Category:Genetic disorders]]
[[Category:RTT]]
[[Category:Neurocutaneous syndromes]]

Latest revision as of 01:53, 20 March 2025


Neurofibromatosis
Synonyms N/A
Pronounce N/A
Field Neurosurgery, Genetics
Symptoms Skin lumps, scoliosis, hearing loss, vision loss<ref name=NIH2016/>
Complications Tumor growth, neurological issues, learning disabilities
Onset Birth to early adulthood<ref name=NIH2016/>
Duration Lifelong<ref name=NIH2016/>
Types Neurofibromatosis type 1 (NF1), Neurofibromatosis type 2 (NF2), Schwannomatosis<ref name=NIH2016/>
Causes Genetic mutation (inherited or spontaneous)<ref name=NIH2016/>
Risks N/A
Diagnosis Clinical symptoms, genetic testing, imaging studies<ref name=Gen2016/>
Differential diagnosis N/A
Prevention N/A
Treatment Surgery, radiation therapy, chemotherapy, cochlear implants<ref name=Gen2016/>
Medication N/A
Prognosis NF1: normal life expectancy<ref name=NIH2016/>
NF2: shortened life expectancy<ref name=NIH2016/>
Frequency 1 in 3,000 people (United States)<ref name=NIH2016/>
Deaths N/A


Neurofibromatosis (NF) is a group of genetic disorders that cause the growth of tumors in the nervous system.<ref name="NIH2016">

Neurofibromatosis Fact Sheet(link). NINDS.

3 February 2016.



</ref> It includes three distinct conditions:

The tumors in neurofibromatosis are generally benign (non-cancerous), but they can sometimes become malignant.<ref name=NIH2016/>

Signs and Symptoms[edit]

The symptoms vary depending on the type of neurofibromatosis and may include:

Neurofibromatosis Type 1 (NF1)[edit]

  • Skin changes – Café au lait spots, freckling in the underarms or groin.
  • Nerve tumors – Neurofibromas, which can appear under the skin or deeper in the body.
  • Bone abnormalities – Scoliosis (curved spine) or abnormal bone development.
  • Learning disabilities – Mild intellectual disability or attention deficit issues.
  • Eye involvement – Lisch nodules (tiny brown spots on the iris), optic gliomas (tumors affecting vision).

Neurofibromatosis Type 2 (NF2)[edit]

  • Hearing loss – Due to bilateral vestibular schwannomas (tumors on the auditory nerves).
  • Balance issues – Difficulty with coordination and dizziness.
  • Vision problems – Early cataracts and other eye issues.
  • Facial weakness or numbness – Due to tumors affecting cranial nerves.

Schwannomatosis[edit]

  • Chronic pain – Often the first symptom.
  • Multiple schwannomas – Benign tumors along nerves, but without affecting hearing.
  • Nerve compression symptoms – Tingling, weakness, or numbness in affected areas.

Causes and Genetics[edit]

Neurofibromatosis is genetic, caused by mutations in different genes:

  • NF1 – Mutation in the NF1 gene on chromosome 17, affecting neurofibromin, a tumor suppressor.
  • NF2 – Mutation in the NF2 gene on chromosome 22, affecting merlin, another tumor suppressor.
  • Schwannomatosis – Mutations in the SMARCB1 or LZTR1 genes, also on chromosome 22.

NF is an autosomal dominant disorder, meaning only one parent needs to have the mutation for a child to inherit it. However, about 50% of cases arise from a spontaneous mutation, with no family history.<ref name="Gen2016">

Learning about Neurofibromatosis(link). National Human Genome Research Institute (NHGRI).

16 August 2016.



</ref>

Diagnosis[edit]

The diagnosis is based on:

  • Clinical symptoms – Skin findings, nerve tumors, hearing issues.
  • Medical imaging – MRI or CT scans to detect tumors.
  • Genetic testing – Confirms the presence of NF-related mutations.
  • Eye exams – To check for Lisch nodules or optic gliomas.

Treatment and Management[edit]

There is no cure for neurofibromatosis, but treatment focuses on managing symptoms and complications.

Surgical and Medical Interventions[edit]

  • Tumor removal – If tumors cause significant symptoms, surgery may be required.
  • Radiation therapy – Used for tumors that cannot be surgically removed.
  • Chemotherapy – In cases where tumors become cancerous.
  • Hearing aids or cochlear implants – Help manage hearing loss in NF2.

Supportive Care[edit]

  • Physical therapy – Helps with movement and balance issues.
  • Pain management – Medications for schwannomatosis-related chronic pain.
  • Educational support – For NF1-related learning disabilities.

Prognosis[edit]

The outlook depends on the type:

  • NF1 – Generally mild, with a normal life expectancy.
  • NF2 – More severe; hearing loss and neurological complications may shorten life expectancy.
  • Schwannomatosis – Pain is the main concern, but it does not typically affect lifespan.

Epidemiology[edit]

  • NF1 affects 1 in 3,000 people.
  • NF2 affects 1 in 25,000 people.
  • Schwannomatosis affects 1 in 40,000 people.

Males and females are affected equally.<ref name=NIH2016/>

History[edit]

  • 1st Century – Early descriptions of neurofibromatosis.
  • 1882 – Friedrich Daniel von Recklinghausen formally describes NF1.
  • 1990s-Present – Advancements in genetic testing and targeted therapies.

Related Conditions[edit]

See Also[edit]

External Links[edit]




This article is a medical stub. You can help WikiMD by expanding it!
PubMed
Wikipedia